Kenworthy Capital

Kenworthy Capital is an early-stage impact investment fund with the intention to generate positive, measurable social and environmental impact alongside a financial return. Kenworthy Capital investments are focused in two main areas:

· Autoimmune Diseases — More than 80 diseases occur as a result of the immune system attacking the body’s own organs, tissues, and cells. Some of the more common autoimmune diseases include type 1 diabetes, celiac, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.

Although the causes of many autoimmune diseases remain unknown, a person’s genes in combination with infections and other environmental exposures are likely to play a significant role in disease development. Treatments are available for many autoimmune diseases, but cures have yet to be discovered.[1]

· Climate Change — Climate change represents one of the greatest threats of our time. There is a wide variety of problem that needs addressing these include the social issues such as, alleviating the impact from climate change-induced extreme weather events, reducing air pollution in cities, addressing ocean plastics, transforming our energy system to clean energy or sustainable ways of food production, to providing access to quality education and healthcare. Supporting efforts in the public and private sector to address and solve the challenges of climate change is a core mission of Kenworthy Capital

Kenworthy Capital is currently fully funded but open to investor inquiries for a second stage of funding. To learn more about Kenworthy Capital please see our website:https://www.randalkenworthy.com/kenworthy-capital

Kenworthy Capital is a supporter of the UN Principles for Responsible Investment.

[1]https://www.niaid.nih.gov/diseases-conditions/autoimmune-diseases